Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Cyclerion Therapeutics (CYCN) Shares Issued (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Shares Issued for 5 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For Q3 2025, Shares Issued changed N/A year-over-year to $1.8 million; the TTM value through Sep 2025 reached $3.2 million, changed N/A, while the annual FY2023 figure was $24000.0, N/A changed from the prior year.
  • Shares Issued hit $1.8 million in Q3 2025 for Cyclerion Therapeutics, up from $1.4 million in the prior quarter.
  • Across five years, Shares Issued topped out at $12.5 million in Q4 2021 and bottomed at -$17000.0 in Q3 2022.
  • Average Shares Issued over 3 years is $2.0 million, with a median of $85000.0 recorded in 2021.
  • Year-over-year, Shares Issued soared 2600.0% in 2021 and then crashed 145.95% in 2022.
  • Cyclerion Therapeutics' Shares Issued stood at $12.5 million in 2021, then plummeted by 100.14% to -$17000.0 in 2022, then surged by 10688.24% to $1.8 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $1.8 million, $1.4 million, and -$17000.0 for Q3 2025, Q1 2025, and Q3 2022 respectively.